Skip to main content

COVID-19 Diagnostics Market Size Worth USD 8.04 Billion at 2.7% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for R&D Activities: Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, India, March 01, 2021 (GLOBE NEWSWIRE) — The global COVID-19 diagnostics market size is projected to reach USD 8.04 billion by 2027, exhibiting a CAGR of 2.7% during the forecast period. Uncontrolled spread of the coronavirus worldwide will be the major factor propelling the growth of this market, shares Fortune Business Insights™ in its report, titled “COVID-19 Diagnostics Market Size, Share & Industry Analysis, By Product (Instruments and Reagents & Kits), By Technology (PCR (Polymerase Chain Reaction), ELISA (Enzyme-linked Immunosorbent Assay), Point-of-care (POC), and Others), By Sample Type (Oropharyngeal and Nasopharyngeal Swabs, Blood, Urine, and Others), By End User (Hospitals & Clinics, Laboratories & Diagnostic Centers, Research Institutes, and Others), and Regional Forecast, 2020-2027”.Industry Developments:May 2020: Sofia 2 SARS Antigen FIA test developed by Quidel was green lit by the FDA, making it the first antigen test approved in the US for the detection of COVID-19. These tests identify unique protein fragments found on the outer walls of the coronavirus and deliver quick results.March 2020: The US FDA cleared Abbott’s molecular point-of-care test for detection of COVID in patients through its Emergency Use Authorization (EUA). The test promises to deliver positive results in 5 minutes and negative results in 13 minutes.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/covid-19-diagnostics-market-103291
According to Johns Hopkins University, global COVID-19 infections reached 100,000 in just 60 days, growing to 200,000 in the next 12-14 days, and the recent addition of 100,000 cases has taken only 3 days. The calculation of the spread of this disease is based on the estimation of the “reproduction number” or R Naught (Ro). The UK Research and Innovation organization states that if the Ro goes above 1, exponential growth will be witnessed. As per a study published in the Journal of Clinical Medicine based on the virus transmission rate in Wuhan, the Ro was computed to be between 2.49 and 2.63. Such rapid transmission of the virus has surged the demand for coronavirus diagnostics tools and kits, which is boosting the growth of this market.An Overview of the Impact of COVID-19 on this Market:The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
Click here to get the short-term and long-term impact of COVID-19 on this market.Please visit: https://www.fortunebusinessinsights.com/covid-19-diagnostics-market-103291
Concerted Efforts towards Developing COVID Detection Tests to Accelerate GrowthWith the COVID-19 pandemic showing no signs of abatement, medical and regulatory bodies are collaborating to encourage innovation and speed up research in developing coronavirus detection tools. For instance, in April 2020, the National Institutes of Health in the US announced the launch of Rapid Acceleration of Diagnostics (RADx) initiative with a funding of USD 1.5 billion to commercialize and widen the accessibility of COVID-19 testing.Similarly, in June 2020, the US Food and Drug Administration (FDA) joined the COVID-19 Diagnostics Evidence Accelerator created by the Friends of Cancer Research and Reagan-Udall Foundation with the aim to evaluate the performance of PCR and antibody tests for COVID. Together, these and similar initiatives are expected to augment the COVID-19 diagnostics market growth throughout 2020.High Number of COVID-19 Cases to Give North America Leading Market PositionThe United States is one of the worst-hit countries in the world by the coronavirus pandemic, with the number of cases as of June 2020 standing at 2.68 million and 129,000 deaths. In response, the US government is injecting more funds into medical research facilities to accelerate development of COVID-19 diagnostics and widen the testing net in the country. The region’s market size in 2020 stood at USD 2.20 billion.In Europe, the virus is spreading at a furious pace, with the UK, Italy, Spain, France, and Germany having the highest number of cases. Quick adoption of advanced detection tools in the region will enable it to expand its footprint in the COVID-19 diagnostics market share in the immediate future. Heavy investments by governments in Asia Pacific in the healthcare sector are expected to favor market growth in the region.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/covid-19-diagnostics-market-103291
Regulatory Support to Novel Diagnostic Solutions to Encourage InnovationThe coronavirus is tightening its hold on the world and pharmaceuticals and governments are in a race against time to develop and launch quick and accurate diagnostic tests for this deadly virus. As a result, bodies such as the FDA are providing the necessary support to companies by removing unnecessary regulatory barriers, which is encouraging other players to innovate.List of Key Players Covered in this Market Report:PerkinElmer Inc. (Massachusetts, U.S)Quest Diagnostics Incorporated (New Jersey, U.S)Quidel Corporation (California, U.S)Siemens Healthcare GmbH (Germany)Abbott (Illinois, U.S)Thermo Fisher Scientific Inc. (Massachusetts, U.S)bioMérieux SA (France)F. Hoffmann-La Roche Ltd (Switzerland)Danaher Corporation (Washington D.C, U.S)
Quick Buy –  COVID-19 Diagnostics Market Research Report:https://www.fortunebusinessinsights.com/checkout-page/103291
Detailed Table of Content:IntroductionMarket ScopeMarket SegmentationMarket MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsOverview: Guidelines for COVID-19 DiagnosisNew Product LaunchPrevalence of COVID-19 DiseaseKey Industry Developments – Mergers, Acquisitions, and PartnershipsGlobal COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2016-2027Key Findings / SummaryMarket Analysis, Insights and Forecast – By Product Instruments Reagents & KitsMarket Analysis, Insights and Forecast – By Technology Polymerase Chain Reaction (PCR) Enzyme-linked Immunosorbent Assay (ELISA) Point-of-care (POC) OthersMarket Analysis, Insights and Forecast – By Sample Type Oropharyngeal & Nasopharyngeal Swabs Blood Urine OthersMarket Analysis, Insights and Forecast – By End User Hospitals & Clinics Laboratories & Diagnostic Centers Research InstituteMarket Analysis, Insights and Forecast – By Geography North America Europe Asia Pacific Latin America Middle East & AfricaNorth America COVID-19 Diagnostics Market Analysis, Insights and Forecast, 2020-2027Key Findings / SummaryMarket Analysis, Insights and Forecast – By Product Instruments Reagents & KitsMarket Analysis, Insights and Forecast – By Technology Polymerase Chain Reaction (PCR) Enzyme-linked Immunosorbent Assay (ELISA) Point-of-care (POC) OthersMarket Analysis, Insights and Forecast – By Sample Type Oropharyngeal & Nasopharyngeal Swabs Blood Urine OthersMarket Analysis, Insights and Forecast – By End User Hospitals & Clinics Laboratories & Diagnostic Centers Research InstituteOthersMarket Analysis, Insights and Forecast  – By CountryU.S.Canada
TOC Continued….
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/covid-19-diagnostics-market-103291
Global COVID-19 Diagnostics Market Segmentation :              

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.